Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02730858 · ClinicalTrials.gov registry record · NA

Palliative and Oncology Care Model in Breast Cancer

A NA study of Metastatic Breast Cancer, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
120
Enrollment target
1
Study location

NCT02730858: Completed NA study of Metastatic Breast Cancer, sponsored by Massachusetts General Hospital.

NCT02730858 is a NA study of Metastatic Breast Cancer that has completed, run by Massachusetts General Hospital. The registered enrollment target is 120 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02730858, a NA study of Metastatic Breast Cancer, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to test a new way to deliver oncology and palliative care for patients with metastatic breast cancer. * The goal of this study is to test a model where oncology and palliative care work together to care for participants with metastatic breast cancer who were recently admitted to the hospital or have new or worsening cancer involving their brain or the fluid around the brain or spinal cord. * The investigators are studying whether participants who receive care from both teams have better communication about their care and improved quality of life and mood compared to those receiving care from only their oncologists. The purpose of this randomized clinical trial is to conduct a randomized trial testing the impact of the collaborative palliative and oncology care model or standard oncology care models among patients with poor prognosis metastatic breast cancer. Participants assigned to the intervention arm will participate in a series of structured palliative care visits, following tailored clinical practice guidelines previously developed for patients with metastatic breast cancer.

Primary Outcome

Compare differences in rate of documentation of end of life care preferences (Yes documented vs. No)

Conditions Studied

Interventions

  • BEHAVIORAL Palliative and Oncology Care
  • BEHAVIORAL Standard Oncology Care

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2016-05
Est. Completion 2023-03
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT02730858 record still lists

NCT02730858 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (41% lower).

The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Palliative and Oncology Care is the first listed.

NCT02730858 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02730858 about?

NCT02730858 is a clinical study titled "Palliative and Oncology Care Model in Breast Cancer". The purpose of this research study is to test a new way to deliver oncology and palliative care for patients with metastatic breast cancer. * The goal of this study is to test a model where oncology and palliative care work together to care for participants with metastatic breast cancer who were re...

What is the current status of trial NCT02730858?

This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2016-05. Estimated completion is 2023-03.

What conditions does trial NCT02730858 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer.

What interventions are being tested in trial NCT02730858?

The interventions under investigation include: Palliative and Oncology Care (BEHAVIORAL), Standard Oncology Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT02730858?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02730858 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02730858's enrollment target sits among peer trials

120 51st of 139 higher than 84 of 139 other Metastatic Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02730858, the US trial registry maintained by the National Library of Medicine. NCT02730858 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.